Researcher calls for greater FDA scrutiny of Epogen dosing

11/8/2006 | Boston Globe (tiered subscription model), The

The FDA needs to do more to protect the safety of kidney dialysis patients who are given high doses of the anemia drug Epogen in clinics, says Dr. Ajay Singh, a clinical chief of the renal division at Brigham and Women's Hospital. Singh, a researcher whose trial of a similar drug had to be halted last year because of safety issues, said there is a trend of higher dosing for dialysis patients and the FDA needs to intervene.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC
Senior Counsel Commercial
RAI Services Company
Winston Salem, NC
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL